Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antigen-specific Cytotoxic T Cells for Opportunistic Infections
NCT03159364Phase 2Terminated
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Jun 2026
- Primary completion
- Jul 2026
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of pathogen-specific CTLs in opportunistic infection, Epstein-Barr virus infection, cytomegalovirus infection (CMV), adenovirus infection, BK virus infection, sponsored by Shenzhen Geno-Immune Medical Institute. Started Jun 2026; status: terminated.
02
Drugs
pathogen-specific CTLs
03
Conditions
opportunistic infectionEpstein-Barr virus infectioncytomegalovirus infection (CMV)adenovirus infectionBK virus infection
Beyond the preview
Go deeper on NCT03159364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03159364.